Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Biomarker Detection Using NAPPA Tumor Antigen Arrays: EDRN Supplement

Biomarker Detection Using NAPPA Tumor Antigen Arrays: EDRN Supplement

190

No coordinating investigator defined.

No involved investigator sites defined.

Broad based screen of possible biomarkers. p53 is included here. ALG10, ATF3, ATP6AP1, BDNF, BMX, C15orf48, CTBP1, DBT, EIF3E, FRS3, BAT4, GPR157, HOXD1, MYOZ2, PDCD6IP, RAB5A, RAC3, SELL, SERPINH1, SF3A1, SLC33A1, SOX2, TFCP2, TRIM32, UBAP1, ZMYM6, ZNF510
Proteomics
Breast and Gynecologic Cancers Research

The overall goal of this project application for the EDRN set-aside funds is to focus our collaborative efforts to identify p53 mutation-specific antibody biomarkers in breast, prostate, and ovarian cancer. P53-specific gene mutations are frequent in multiple cancer types. Of the common solid tumors, p53 mutations have been identified in 50% of lung and ovarian cancers, 45% of colon cancers, 20% of breast cancers, and 10-30% of prostate cancers (The p53 Mutation Handbook, T. Soussi, http://p53/free/fr). The most common mutations vary from cancer to cancer, with 50 point mutations covering the 10 most common mutations for all major solid tumors

1.B. Project Objectives Aim 1: Generation of NAPPA protein microarrays expressing the fifty most common p53 point mutations for solid tumors as well as deletion constructs of p53. Aim 2: Identify p53 mutation-specific antibodies in a test set of breast, prostate, and ovarian cancer patient sera. a.   Using test sera from patients with prostate, ovarian, and breast cancers, identify patient sera that contain anti-p53 antibodies. b.   Using p53-antibody-positive sera from patients, screen the p53 mutation microarray to identify mutation-specific and domain-specific antibodies c.   Using p53-antibody-negative sera from patients, screen the p53 mutation microarray to identify mutation-specific antibodies d.   Determine the sensitivity and specificity of individual antibodies that distinguish patient sera from normal sera. e.   Determine if mutation-specific antibodies can distinguish tumor types.
Various including quantile regression, Fishers exact, binomial proportion and others. The methods are not yet fixed because we are still in discovery.

No datasets are currently associated with this protocol.


New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.